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Abstract
Background: The bone scan index (BSI) using a computer-aided diagnosis system for bone scans is expected to be
an objective and quantitative clinical tool for evaluating bone metastatic prostate cancer. This study aimed to
evaluate the pretreatment BSI as a prognostic factor in hormone-naive prostate cancer patients with bone
metastases.
Methods: The study included 60 patients with hormone-naive, bone metastatic prostate cancer that was initially
treated with combined androgen blockade therapy. The BONENAVI system was used for calculating the BSI. We
evaluated the correlation between overall survival (OS) and pretreatment clinicopathological characteristics,
including patients’ age, initial prostate-specific antigen (PSA) value, Gleason scores, clinical TNM stage, and the BSI.
Cox proportional hazards regression models were used for statistical analysis.
Results: The median follow-up duration was 21.4 months. Clinical or PSA progression occurred in 37 (61.7 %)
patients and 18 (30.0 %) received docetaxel. Death occurred in 16 (26.7 %) patients. Of these deaths, 15 (25.0 %)
were due to prostate cancer. The median OS was not reached. In multivariate analysis, age and the BSI were
independent prognostic factors for OS. We evaluated the discriminatory ability of our models, including or
excluding BSI by quantifying the C-index. The BSI improved the C-index from 0.751 to 0.801 for OS. Median OS was
not reached in patients with a BSI ≤1.9 and median OS was 34.8 months in patients with a BSI >1.9 (p = 0.039).
Conclusions: The pretreatment BSI and patients’ age are independent prognostic factors for patients with
hormone-naive, bone metastatic prostate cancer.
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Background
Prostate cancer is the most common noncutaneous can-
cer, and the second most frequent cause of death from
cancer among men in the USA. In Japan, 11,507 men
were estimated to die of prostate cancer in 2014, making
this disease the sixth leading cause of death from cancer
[1]. The incidence of prostate cancer is lower in Japan
than in the USA and other Western countries. However,
this incidence has been gradually increasing in Japan in
recent years [1]. Huggins and Hodges [2] reported the
efficacy of androgen deprivation therapy for advanced
prostate cancer in 1941. Although 80–90 % of prostate
cancers with metastasis respond to initial androgen abla-
tion therapy, most patients finally develop castration-
resistant prostate cancer (CRPC) [3, 4]. Patients with
CRPC show progression of systemic symptoms and local
* Correspondence: miyoyasu@med.yokohama-cu.ac.jp
†Equal contributors
1Department of Urology and Renal Transplantation, Yokohama City
University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024,
Japan
Full list of author information is available at the end of the article
© 2016 Miyoshi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Miyoshi et al. BMC Cancer  (2016) 16:128 
DOI 10.1186/s12885-016-2176-6
complications. One report showed that the median sur-
vival time among patients with advanced prostate cancer
was 29 to 34 months from initial treatment [5], and an-
other study reported a 5-year survival rate of 20–30 %
[6]. Because these reports showed a wide range of sur-
vival probability, more accurate information on patients’
characteristics related to survival is required.
Several groups have reported prognostic models for
survival of patients with progressive disease [7–10].
Most of these reports were of prognostic models for pa-
tients with CRPC. There are few reports on prognostic
models for patients with metastatic prostate cancer be-
fore treatment. A large study on the prognosis of pa-
tients with pre-hormonal therapy prostate cancer was
reported in Japan and the USA [9]. However, in this previ-
ous study, the endpoint was not survival, but recurrence.
Previously, we reported a nomogram for overall survival
(OS) of patients with bone-metastatic, hormone-naive pros-
tate cancer [7]. This nomogram comprised five pretreat-
ment prognostic factors (patient’s age, clinical T stage,
classification of bone metastasis extension [extent of disease
on bone scan, EOD scores] [11], Gleason scores, and PSA)
selected by multivariate analysis. Among these prognostic
factors, only EOD scores are subjective and semi-
quantitative. Therefore, an objective and quantitative scor-
ing system for evaluation of bone metastasis might be ideal
and warranted. Recently, a computer-aided diagnosis sys-
tem (BONENAVI) for bone scans has been developed. The
BONENAVI system can calculate the “bone scan index
(BSI)”, which provides an objective and quantitative meas-
ure of the percentage of the skeleton involved by bone me-
tastases [12]. It is anticipated that a BSI that uses a
computer-aided diagnosis system for bone scans will be-
come an objective and quantitative clinical tool for evaluat-
ing bone metastatic prostate cancer. The BSI has been
reported as being useful as a survival predictor among men
with prostate cancer with various conditions such as
hormone-naive prostate cancer or CRPC [13, 14].
In this study, we analyzed the relationship between the
prognosis of prostate cancer and pretreatment clinical
factors, including the BSI as calculated by BONENAVI
for OS of patients with bone metastasis. This study
aimed to determine whether the BSI is useful as a prog-
nostic marker of hormone-naive, pretreatment prostate
cancer with bone metastasis.
Methods
Patients and treatments
From 2010–2014, 60 consecutive patients with bone-
metastatic prostate cancer were treated at Yokohama
City University Hospital and associated hospitals. All of
the patients already had metastasis at the time of diag-
nosis, and none of the patients had been previously
treated. This study was a retrospective cohort study.
This study was approved by institutional review board of
Yokohama City University Medical Center and all sub-
jects signed a written informed consent form.
All of the patients had adenocarcinoma of the prostate,
confirmed histologically, with distant metastasis (any T,
any N, M1b-c). The 2009 TNM clinical staging system
and 2005 International Society of Urologic Pathology
Gleason grading system were used. In all of the patients,
the clinical stage was evaluated by chest and body com-
puted tomography and bone scans. Based on the number
or extent of metastases, the scans were divided into the
following five grades according to the EOD on the bone
scan [8]: 0, normal or abnormal due to benign bone dis-
ease; 1, fewer than six bony metastases, each of which is
less than 50 % of the size of a vertebral body (one lesion
approximately the size of a vertebral body was counted
as two lesions); 2, from 6–20 bone metastases, sized as
described above; 3, more than 20 metastases, but fewer
than those observed in a “superscan”; and 4, a “super-
scan” or its equivalent (i.e., more than 75 % of the ribs,
vertebrae, and pelvic bones).
Each hospital used the same treatment protocol. All of
the patients were initially treated with androgen
deprivation therapy (medical or surgical castration with or
without anti-androgen). None of the patients received
prostatectomies or radiation therapy as initial treatments.
After failed initial androgen ablation therapy, almost all of
the patients subsequently underwent substitution treat-
ment comprising anti-androgen therapy, anti-androgen
withdrawal therapy, and/or oral low-dose steroid therapy.
Some patients received bisphosphonate and cytotoxic
therapy, such as docetaxel or estramustine, after develop-
ment of CRPC. None of the patients received abiraterone,
enzalutamide, sipuleucel-T, or cabazitaxel because abira-
terone, enzalutamide, and cabazitaxel were not approved
until 2013, and sipuleucel-T has not been approved yet in
Japan. In the terminal state, palliative therapy and pain
control with morphine, palliative external beam radiation,
and strontium were used as appropriate. Progression was
defined according to recommendations of the Cancer
Clinical Trials Working Group 2 (PCWG2) [15].
Bone Scan Index (BSI)
The automated method for analysis of anterior and pos-
terior whole-body bone scan images has been described
previously [16]. Each individual hot spot was classified
as metastasis or no metastasis by an artificial neural net-
work. The BSI was calculated as the percentage of the
sum of all hot spots classified as bone metastases by the
artificial neural network values. For calculation of the
BSI, we used BONENAVI version 2 (Fujifilm RI Pharma,
Co. Ltd., Tokyo, Japan; Exini Bone, Exini Diagnostics,
Lund, Sweden) [17].
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Statistical analysis
Spearman’s rank correlation coefficient was used for ana-
lysis of the correlation between EOD scores and the BSI.
If there was a strong correlation, these two factors were
not analyzed simultaneously because of multicollinearity.
We investigated the usefulness of a BSI as a predictor
of OS. Univariate and multivariate analysis of OS was
performed using a Cox proportional hazards regression
model with stepwise regression analysis. Relative risks
and 95 % confidence intervals (CIs) were derived. In uni-
variate or multivariate analysis, all variables (age, PSA,
Gleason scores, clinical TNM stage, and the BSI) were
analyzed as binary variables. The cutoff point for all vari-
ables were determined using the median value of each
variable. The C-index was used for discriminatory ability
of our models.
The Kaplan–Meier product-limit estimator was used
to estimate the distribution of survival. The log-rank test
was used for analysis of the survival differences between
patients with a BSI over the cut-off value and patients
with a BSI under the cut-off value.
All tests were two-sided, and the significance level was
fixed at alpha = 0.05. All analyses were conducted with
IBM SPSS Statistics for Windows, ver. 22 (IBM Corp.,
Armonk, NY) and the R stats package (R Foundation for
Statistical Computing, Vienna, Austria).
Results
The characteristics of the patients are listed in Table 1.
The median age of the patients was 72 years and the me-
dian follow-up duration was 21.4 months. The median
initial PSA value was 247.0 ng/ml. The median BSI was
1.9 % (range: 0.0–13.2 %). Zoledronic acid was used for
28 (46.7 %) patients. Clinical or PSA progression oc-
curred in 37 (61.7 %) patients and 18 (30.0 %) received
docetaxel.
The correlation of EOD scores and the BSI is shown in
Fig. 1. The median BSI stratified by EOD 1, 2, 3, and 4 was
0.38, 1.60, 7.38, and 9.29, respectively. There was a signifi-
cant correlation between EOD and the BSI (rs = 0.769). Be-
cause of the strong correlation, we did not analyze the BSI
and EOD in multivariate analysis simultaneously owing to
multicollinearity.
Death occurred in 16 (26.7 %) patients. Of these pa-
tients, 15 (25.0 %) deaths were due to prostate cancer.
The median OS was not reached.
In univariate analysis, age (≤72 years old vs >72 years
old, hazard ratio (HR): 4.136, 95 % confidential interval
(CI): 1.332–12.843, p = 0.014) and BSI (>1.9 % vs ≤1.9 %,
HR: 2.921, 95 % CI: 1.006–8.483, p = 0.049) were prog-
nostic factors for OS (Table 2).
In multivariate analysis, age (≤72 years old vs >72 years
old, HR: 5.811, 95 % CI: 1.656–20.386, p = 0.006) and
BSI (>1.9 % vs ≤1.9 %, HR: 4.676, 95 % CI: 1.238–17.661,
p = 0.023) were independent prognostic factors for OS.
(Table 2).
We evaluated the discriminatory ability of our models
by quantifying the C-index. The C-index of our model
including BSI was 0.801 for OS. We also analyzed the
discriminatory ability of the model excluding BSI and
the model including EOD instead of BSI by quantifying
the C-index. The C-index of the models excluding BSI
was 0.751 for OS. The C-index of the models including
EOD instead of BSI was 0.811.
We compared the survival probability by BSI categories.
Median OS was not reached in patients with a BSI ≤1.9
and median OS was 34.8 months in patients with a
BSI >1.9 (p = 0.039) (Fig. 2).
Table 1 Patients’ characteristics (n = 54)
Median age, years (range) 72 (55–89)
Median observation period, months (range) 21.4 (0.9–57.8)
Median PSA, ng/mL (range) 247.0 (9.7–4206.0)
PSA distribution, n (%)
<10 ng/mL 1 (1.7)
10- < 20 ng/mL 2 (3.3)
20- < 100 ng/mL 15 (25.0)
100- < 500 ng/mL 20 (33.3)
≥500 ng/mL 22 (36.7)











N stage, n (%)
N0 24 (40.0)
N1 36 (60.0)
M stage, n (%)
M1b 51 (85.0)
M1c 9 (15.0)






PSA prostate-specific antigen, BSI bone scan index, EOD extent of disease
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Discussion
Several groups have reported prognostic models for sur-
vival of patients with progressive prostate cancer [7–10].
Almost all reports were of prognostic models of patients
with CRPC. However, only a few reports have described
prognostic models for hormone-naive progressive pros-
tate cancer before treatment [10, 18–20].
Hussain et al. [21] reported various risk predictors of
OS (SWOG9346). They identified baseline variables,
such as bone pain, performance status, Gleason sum,
weight change, positive lymph node metastasis, pre-
study PSA increments, and PSA levels after treatment as
strong prognostic factors for OS. Coopeberg et al. [9]
also reported a large study on prostate cancer prognosis
in hormone-naive patients in Japan and the USA. They
assessed 13,740 US men and 19,265 Japanese men with
prostate cancer and developed the Japan Cancer of the
Prostate Risk Assessment (J-CAPRA). The CAPRA
score, which ranges from 0–12, and is based on the
Gleason sum, serum PSA levels at initial treatment, and
clinical stage, can predict progression-free survival after
primary androgen deprivation therapy. Although the
endpoint of the J-CAPRA is progression-free survival,
we are interested in developing an OS prognostic model
for patients with hormone-naive metastatic prostate can-
cer. Progression-free survival is predictive of OS in men
with CRPC [22], although the association between
progression-free survival and OS is relatively weak.
Some reports have indicated improvement in OS with-
out an increase in progression-free survival [23] or
Fig. 1 Correlation of EOD classification and the BSI. Box plots indicate the first and third quartiles. The band inside the box shows the median.
Lines extending vertically from the boxes (whiskers) indicate variability outside the upper and lower quartiles. There was a significant correlation
between EOD and the BSI (rs = 0.769). BSI; bone scan index, EOD; extent of disease on bone scan
Table 2 Univariate and multivariate analysis for overall survival
Univariate analysis Multivariate analysis
p value Hazard ratio 95.0 % CI p value Hazard ratio 95.0 % CI
Lower Upper Lower Upper
Age (≤72 years old vs >72) 0.014 4.136 1.332 12.843 0.006 5.811 1.656 20.386
PSA (>247 ng/mL vs ≤247 ng/mL) 0.981 1.012 0.379 2.703 0.407 0.621 0.201 1.914
Gleason score (10–8 vs ≤7) 0.983 1.017 0.228 4.543 0.617 1.640 0.236 11.403
T stage (4 vs ≤3) 0.239 1.908 0.651 5.588 0.137 2.576 0.741 8.953
N stage (1 vs 0) 0.723 1.198 0.441 3.255 0.251 2.035 0.605 6.843
M stage (1c vs 1b) 0.744 0.780 0.176 3.462 0.467 0.524 0.092 2.990
BSI (>1.9 % vs ≤1.9 %) 0.049 2.921 1.006 8.483 0.023 4.676 1.238 17.661
PSA prostate-specific antigen, BSI bone scan index
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improvement in progression-free survival without an in-
crease in survival [24]. Accurate prediction models for
prostate cancer survival probability would be helpful for
counseling of patients.
In previous studies, EOD was reported to be a strong
predictor of survival [7, 8]. EOD classification is used for
evaluation of bone metastases. Because EOD is a sub-
jective and semi-quantitative factor, more accurate and
objective parameters for evaluation of spread of bone
metastasis are warranted. Recently, the BSI, using a
computer-aided diagnosis system for bone scans, has
been expected to be an objective and quantitative clinical
tool for evaluation of bone metastatic prostate cancer.
The BSI is useful for prediction of survival in men with
prostate cancer in various situations, such as hormone-
naive cancer or CRPC [11, 13, 14, 25–29]. In this study,
we measured BSI using BONENAVI version 2, which is a
computer-assisted diagnosis system for bone scanning.
BONENAVI version 2 software is based on a multi-center
database and it showed excellent sensitivity and specificity
for diagnosis of skeletal metastasis [17, 30].
In the hormone-naive setting, usefulness of the BSI as
prognostic marker was reported by Koboteh and Poulsen
[13, 27]. Koboteh and colleagues [27] reported that the
BSI and Gleason scores were independent predictive fac-
tors of survival in men with a high risk of prostate can-
cer who were treated by androgen ablation therapy,
although clinical stage and pre-treatment PSA levels
were not prognostic factors. Poulsen et al. [13] also re-
ported that only the BSI was an independent prognostic
factor for survival of men with metastatic prostate can-
cer, although PSA and Gleason scores were not.
In our study, we analyzed the correlations between
survival and clinical factors, including age, pre-treatment
PSA levels, Gleason scores, clinical TNM classifications,
and the BSI using the Cox proportional hazard regres-
sion model. EOD scores were significantly associated
with the BSI value. EOD scores were not included in
multivariate analysis because of multicollinearity. In re-
sults, patients’ age and the BSI were independent prog-
nostic factor for OS of men with metastatic, hormone-
naive prostate cancer. Because the BSI is continuous var-
iables, the BSI is more ideal and accurate for prediction
of individual patient’s prognosis compared with EOD
scores. Moreover, we evaluated the discriminatory ability
of our models by quantifying the C-index. The C-index
of our model including BSI was 0.801 for OS. We also
analyzed the discriminatory ability of the model exclud-
ing BSI and the model including EOD instead of BSI by
quantifying the C-index. The C-index of the model ex-
cluding BSI was 0.751 for OS. The C-index of the
models including EOD instead of BSI was 0.811.
A limitation of this study is the fact that patients who
were enrolled in the study had various health statuses
and complications. Our models did not consider health
status or patients’ complications that may affect prostate
cancer treatment outcomes [21, 31, 32]. Patients with
prostate cancer are much older than those with other
malignancies. Health status and complications should be
classified in the rating score and included as predictive
factors in the prognostic model. Our study did not in-
clude blood data. In previous studies, blood data, such
as serum hemoglobin, alkaline phosphatase, lactate de-
hydrogenase, and C-reactive protein were reported as
Fig. 2 Kaplan–Meier curve for overall survival according to the bone scan index (BSI). The blue line indicates survival for patients with a BSI >1.9
(n = 30) and the green line indicates survival for patients with a BSI ≤1.9 (n = 30) (p =0.039)
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survival predictive factors for patients with prostate can-
cer [19, 20, 33]. Bone pain at diagnosis is also a strong
predictor of survival [21]. Unfortunately, data regarding
pain at baseline were not available in this study. Lack of
data about PSA kinetics was also limitation of our study.
Finally, our population was small, observation periods
were relatively short, and number of event was also
small. Thus, some of the estimates have wide confiden-
tial intervals. More large populations and long observa-
tions are required for establishing the usefulness of the
BSI as a prognostic factor. Although some study limita-
tions exist, the BSI before treatment might be useful for
a prognostic biomarker of hormone-naive, bone meta-
static prostate cancer.
Conclusion
The pretreatment BSI and patients’ age are independent
prognostic factors for patients with hormone-naive, bone
metastatic prostate cancer. Compared with EOD, the
BSI is a quantitative and objective factor for assessing
bone metastases, and a more ideal factor for predicting
prognosis in men with metastatic, hormone-naive pros-
tate cancer.
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